R. M. Stone

Phase 1 Study of PKC412, an Oral FLT3 Kinase Inhibitor, in Sequential and Concomitant Combinations with Daunorubicin and Cytarabine (DA) Induction and High-Dose Cytarabine (HDAra-C) Consolidation in Newly Diagnosed Patients with AML.

Francis G. Giles, Charles A. Schiffer, Hagop M. Kantarjian et al. · Blood · 2004 · 71 citations

Medicine, Oncology, Pharmacology +13

Torsades de pointes associated with voriconazole use

Jemima Philips, Francisco M. Marty, R. M. Stone et al. · Transplant Infectious Disease · 2007 · 66 citations

Medicine, Cardiology, Pharmacology +17

GAS6 expression identifies high-risk adult AML patients: potential implications for therapy

Susan P. Whitman, Jessica Kohlschmidt, Kati Maharry et al. · Leukemia · 2013 · 57 citations · Full text

Medicine, Hematology, Oncology +4

Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720

Maria R. Baer, SL George, B. Sanford et al. · Leukemia · 2011 · 27 citations · Full text

Medicine, Oncology, Pharmacology +16

Treatment for Myelodysplastic Syndromes

David R. Spriggs, R. M. Stone, Donald Küfe · The Lancet · 1987 · 27 citations

Medicine, Hematology, Chemotherapy +10